Patients With Rheumatoid Arthritis (RA) Treated With Rituximab in Kuopio University Hospital

One Centre Follow-up Study on Safety and Efficacy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00854321

Acronym

KuoRituxi1

Enrollment

Registered

2009-03-03

Start date

2004-11-30

Completion date

2008-07-31

Last updated

2009-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Keywords

rheumatoid arthritis, rituximab, therapy

Brief summary

One centre follow-up study on safety and efficacy of treatment with rituximab among patients with RA during 4 year period. Basic data is collected for the national register of biologicals.

Detailed description

Data is collected on regular visits in the outpatient department. In collection national register forms have been used.

Interventions

DRUGrituximab

rituximab two 1000 mg intravenous infusions separated by two weeks

DRUGrituximab, observational study amon patients with active RA

two 1000 mg intravenous infusions separated by 2 weeks

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* active RA without response to earlier treatment

Exclusion criteria

* contraindications to rituximab

Design outcomes

Primary

Measure	Time frame
ACR20 ACR50 ACR70 response	6 and 12 months

Secondary

Measure	Time frame
Duration of clinical response	6 and 12 months

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026